AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00836251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: H218O and 2H2O, administered as a mixed cocktail
Description: 0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
Study NCT01701076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Induction treatment phase (cycle 1-6):~* Bendamustine 75 mg/m2 i.v day 1 and 2~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~* Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
Study NCT01638078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks
Study NCT01638078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, pill, once p.d., 6 weeks
Study NCT03819036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
Study NCT01817283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptolide
Description: Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
Study NCT01817283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triptolide
Description: Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
Study NCT01817283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Study NCT01817283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Study NCT01817283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills produced the same as Triptolide wilfordii.
Study NCT01091688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-Time information
Description: Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
Study NCT01214863 — intervention group
Intervention type: DEVICE
Intervention: T3
Description: Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
Study NCT01214863 — intervention group
Intervention type: DEVICE
Intervention: T4
Description: Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
Study NCT01214863 — intervention group
Intervention type: DEVICE
Intervention: T5
Description: Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
Study NCT00865904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: Capsules
Study NCT00865904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-809 capsules.
Study NCT02566577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh red blood cell (RBC) transfusion
Description: 1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (\<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
Study NCT02566577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Storage-aged red blood cell (RBC) transfusion
Description: 1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
Study NCT02566577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic infusion pump
Description: A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
Study NCT03353974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video game therapy
Description: Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
Study NCT03353974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance platform therapy
Description: Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
Study NCT03591354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM
Description: Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology \& Dexcom G6 CGM for 3 months.
Study NCT03591354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: t:slim X2 with Basal-IQ & Dexcom G6 CGM
Description: Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
Study NCT00572962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
Description: use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
Study NCT04404322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPT A Suicide Crisis Intervention
Description: The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
Study NCT04404322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
Study NCT04651543 — intervention group
Intervention type: OTHER
Intervention: X-Ray
Description: X-ray obtained at one-week of the fracture
Study NCT03015519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: 30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
Study NCT03015519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
Study NCT02372916 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Description: The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
Study NCT02630732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain school
Description: 2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
Study NCT02630732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back school
Description: Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
Study NCT03052504 — intervention group
Intervention type: OTHER
Intervention: Registration of complications
Description: Prospective registration
Study NCT02650336 — intervention group
Intervention type: DRUG
Intervention: contrast
Description: a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
Study NCT01929239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PSMA Designer T Cells
Study NCT01759004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: volume, muscle strength, physical condition, BMI
Description: phys. condition, muscle strength, volumetry, BMI
Study NCT04353479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab(SHR-1210)
Description: A humanized monoclonal immunoglobulin
Study NCT04353479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: A DNA methyltransferase inhibitor
Study NCT02629796 — intervention group
Intervention type: OTHER
Intervention: CIDP treated (IVIG)
Description: usual treatment with intravenous immunoglobulin
Study NCT01761825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine
Study NCT03180164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hospital anxiety and depression scale
Description: self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
Study NCT03664154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Feeding (SAFE)
Description: The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls.
Study NCT03275181 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: Non-invasive assessment of left ventricle structure and function
Study NCT03275181 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood pressure
Description: Continuously monitored for 5-30 minutes via finger photoplethysmography
Study NCT03275181 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal Exercise
Description: Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
Study NCT05106673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal pathways to care
Description: The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
Study NCT05106673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and training program for the professionals
Description: The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
Study NCT05106673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic screening
Description: The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
Study NCT05106673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
Study NCT00189618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 100mg p.o. OD
Study NCT00189618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg p.o. OD
Study NCT00643526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled Auto-injector Containing Placebo
Description: Participants will self-inject placebo subcutaneously at thigh and abdomen.
Study NCT01244295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment
Description: Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
Study NCT01244295 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Therapy
Description: Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
Study NCT03126396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgo 310 3166 dressing
Description: Experimental: Urgo 310 3166 dressing
Study NCT02395081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D3 in prenatal vitamin
Description: Women will receive 2000 IU 25(OH)D in prenatal vitamin.
Study NCT02395081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4000 IU Vitamin D3 in prenatal vitamin
Description: Women will receive 4000 IU 25(OH)D in prenatal vitamin.
Study NCT00926861 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: A-scan and B-scan ultrasound at baseline and month 6,12,24
Study NCT00926861 — intervention group
Intervention type: DEVICE
Intervention: OCT
Description: Volume scans of spectralis OCT at baseline and month 6,12,24
Study NCT04360499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low- weight-high-repetitions training
Description: LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions
Study NCT04360499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates training
Description: Pilates style exercise training
Study NCT02408107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
Study NCT04630587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect restorations
Description: see the Arm description
Study NCT04630587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect restorations
Description: see the Arm description
Study NCT02289651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venner
Description: Video-laryngoscopy
Study NCT02289651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct-Laryngoscopy
Study NCT03882203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAGE-FluBu
Description: Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
Study NCT03848754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 3 mg/m^2
Description: GO 3 mg/m\^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle.
Study NCT03848754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 2 mg/m^2
Description: GO 2 mg/m\^2 on Day 1 of a 28-day cycle.
Study NCT03848754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat - 45 mg
Description: Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
Study NCT03848754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat - 60 mg
Description: Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
Study NCT01772901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine Intervention
Description: The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
Study NCT00699803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-PRED
Description: T-PRED sterile ophthalmic solution
Study NCT00699803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: Pred Forte sterile ophthalmic solution
Study NCT02761395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Al-hijamah
Description: * Strict sterilization of selected anatomical sites.~* Suction using sterile plastic disposable sucking cups~* Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.
Study NCT02761395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 20-40 mg/kg/day orally
Study NCT02761395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: 20-40 mg/kg/day orally
Study NCT00763230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
Study NCT00763230 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.